Abbas, D., Chong, E. and Raymond, E.. Outpatient medical abortion is safe and effective through 70days gestation. Contraception, 2015;92(3), pp.197-199.

Aiken ARA, Digol I, Trussel J, Gomperts R. Self Reported Outcomes and Adverse Events After Medical Abortion Through Online Telemedicine. BMJ. 2017 May 16;357:j2011.

Aiken A, Starling J, Scott, J. Association of Texas Senate Bill 8 with Requests for Self-Managed Medication Abortion. JAMA Network Open. 2022;5(2):e221122. doi:10.1001/jamanetworkopen.2022.1122.

Aiken A, et al., 2021. Effectiveness, safety and acceptability of no‐test medical abortion provided via telemedicine: a national cohort study. BJOG: An International Journal of Ob/Gyn, 128(9), pp.1464-1474.

Akin MD, Weingand KW, Hengehold DA, et al. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstetrics & Gynecology, 2001; 97(3), pp.343-349.

Ashok, PW, Penney GC, Flett GMM, et al. An effective Regimen for Early Medical Abortion:  A Report of 200 Consecutive Cases. Hum Reprod 1998;13:2962-2965.

Barnhart K, Hansen KR, Stephenson MD, et al. Effect of an Active vs Expectant Management Strategy on Successful Resolution of Pregnancy Among Patients With a Persisting Pregnancy of Unknown Location: The ACT or NOT Randomized Clinical Trial. JAMA. 2021 Aug 3;326(5):390-400.

Blum J, Raghavan S, Dabash R, et al. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet. 2012;118:166-71.

Boersma AA, Meyboom-de Jong B, Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea. Eur J Contracept Reprod Health Care. 2011 Apr;16(2):61-6.

Bracken H, Clark W, Lichtenberg ES, et al. Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone–misoprostol. BJOG. 2011;118(1):17-23.

Bracken H, Dabash R, Tsertsvadze G,  et al. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days’ LMP: a prospective open-label trial. Contraception. 2014 Mar;89(3):181-6.

Brandi K, Woodhams E, White K O, et al. An exploration of perceived contraceptive coercion at the time of abortion. Contraception. 2018 Apr;97(4):329-334.

Chai J, Wong CY, Ho PC. A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days’ gestation. Contraception. 2013 Apr;87(4):480-5.

Chen MJ, Creinin MD. Mifepristone with buccal misoprostol for medical abortion: a systematic review. Obstet Gynecol. 2015 Jul;126(1):12-21.

Creinin MD, Fox MC, Teal S, et al.  A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion.  Obstet Gynecol 2004 May;103(5 Pt 1):851-859.

Creinin MD, Hou MY, Dalton L, et al. Mifepristone antagonization with progesterone to prevent medical abortion: a randomized controlled trial. Obstet Gynecol. 2020 Jan; 135(1):158-165.

Colwill AC, Bayer LL, Bednarek P, et al. Opioid Analgesia in Medication Abortion: A Randomized Control Trial. Obstet Gynecol 2019 Dec;134(6):1163-1170.

Danco: FDA Package Label; Current Mifeprex materials March 2016.; FDA Mifepristone Q&A 2021.

Dragoman MV, Grossman D, Nguyen MH, et al. Two prophylactic pain management regimens for medical abortion ≤63 days’ gestation with mifepristone and misoprostol: A multicenter, randomized, placebo-controlled trial. Contraception. 2021;103(3):163-170.

Dzuba IG, Castillo PW, Bousiéguez M, et al. A repeat dose of misoprostol 800mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review. 2020 May. Contraception. 2020;S0010-7824(20)30160-8.

Dzuba IG, Chong E, Hannum C, et al. A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation. Contraception. 2020 May;101(5):302-308.

Fiala C, Safar P, Bygdeman M, et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003; 109: 190-195.

Fiastro A, Wells E, Coeytaux F, Godfrey E. ACCESS, DELIVERED: A Toolkit for Providers Offering Medication Abortion. University of Washington ResearchWorks. Published 2021. Accessed [January 2022]

Fjerstad M, Trussell J, Lichtenberg ES, et al. Severity of infection following the introduction of new infection control measures for medical abortion. Contraception. 2011 Apr;83(4):330-5.

Friedlander EKB, Soon R, Salcedo J, Davis J, Tschann M, Kaneshiro B. Prophylactic pregabalin to decrease pain during medication abortion. Obstetrics & Gynecology. 2018;132(3):612-618.

Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception 2015 April 91(4): 269-73.

Goldman AR, Porsch L, Hintermeister A, Dragoman M. Transcutaneous electrical nerve stimulation to reduce pain with medication abortion. Obstetrics & Gynecology. 2020;137(1):100-107.

Grossman D, Grindlay K. Alternatives to Ultrasound for Follow-up After Medication Abortion: A Systemic Review. Contraception. 2011; 83(6):504–510.

Grossman D, et al. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol. 2011 Aug;118(2 Pt 1):296-303.

Grossman D, Grindlay K, Buchacker T, et al. Continuing pregnancy after mifepristone “reversal” of first-trimester medical abortion: a systematic review. Contraception. 2015 Sep;92(3):206-11.

Hamoda H, Ashok PW, Flett GM, et al. Medical Abortion at 64 to 91 days of gestation: a Review of 483 Consecutive Cases. Am J Obstet Gynecol. 2003 May;188(5):1315-9.

Hamoda H, Ashok PW, Flett GM, Templeton Al. A Randomised Controlled Trial of Mifepristone in Combination with Misoprostol Administered Sublingually or Vaginally for Medical Abortion up to 13 Weeks gestation. BJOG. 2005 Aug;112(8):1102-8.

Hollenbach SJ, Cochran M, Harrington A.”Provoked” feto-maternal hemorrhage may represent insensible cell exchange in pregnancies from 6 to 22 weeks gestational age. Contraception. 2019 Aug;100(2):142-146.

Horvath S, Tsao P, Huang ZY, et al. The concentration of fetal red blood cells in first-trimester pregnant women undergoing uterine aspiration is below the calculated threshold for Rh sensitization. Contraception 2020.

Hsia JK, Lohr PA, Taylor J, et al. Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days’ gestation. Contraception. 2019;100(3):178-81.

Ipas Clinical Updates in Reproductive Health:

Misoprostol only: Recommended Regimen Before 13 Weeks Gestation. Published 2021.

Recommendations for Abortion At or After 13 Weeks Gestation: Medication Abortion.. Published 2021.

Jones RK, Nash E, Cross L, et al. Medication Abortion Now Accounts for More Than Half of All US Abortions. Guttmacher Institute 2022.

Jones RK, Witwer E, Jerman J. Abortion Incidence and Service Availability in the United States, 2017. Guttmacher Institute, 2019.

Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medication Abortion in the Late First Trimester: A Systematic Review. Contraception. 2019 Feb;99(2):77-86.

KFF. State Restrictions on Telehealth Abortion, 2022.

Kulier R, Kapp N, Gulmezoglu A M, et al. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011 Nov 9;2011(11):CD002855.

Larsson A, Rönnberg AM. Expanding a woman’s options to include home use of misoprostol for medical abortion up until 76 days. Acta Obstet Gynecol Scand. 2019; 98: 747-752.

Lokeland M, Iverson OE, Dahle GS, et al. Medical abortion at 63 to 90 days of gestation. Obstetrics & Gynecology. 2010 May;115(2), 962-968.

Mark A, Foster AM, Grossman D, et al. Forgoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: NAF’s Clinical Policies Committee. Contraception. 2019 May;99(5):265-266.

Meites E, Zane S, Gould C; C. sordellii Investigators. Fatal Clostridium sordellii infections after medical abortions. N Engl J Med. 2010 Sep 30;363(14):1382-3.

Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and misoprostol for abortion through 56 days of LMP. Contraception 2005;72:328-332.

Moreno-Ruiz NL, Borgatta L, Yanow S, Kapp N, Wiebe ER, Winikoff B. Alternatives to Mifepristone for Early Medical Abortion. Int J Gynaecol Obstet. 2007 Mar;96(3):212-8.

Moseson H, Jayaweera R, Egwuatu I, et al. Effectiveness of self-managed medication abortion with accompaniment support in Argentina and Nigeria (SAFE): a prospective, observational cohort study and non-inferiority analysis with historical controls. Lancet Glob Health. 2022 Jan;10(1):e105-e113.

Murtagh C, Wells E, Raymond EG, et al. Exploring the feasibility of obtaining mifepristone and misoprostol from the internet. Contraception. 2017; 92: 297-301.

NAF Clinical Policy Guidelines 2022.

Oppegaard KS, Qvigstad E, Fiala C, et al. Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. Lancet. 2015 Feb 21;385(9969):698-704.

Ralph LJ, Ehrenreich K, Barar R, et al. Accuracy of self-assessment of gestational duration among people seeking abortion. American Journal of Obstetrics and Gynecology. 2021.

Raymond EG, Mark A, Grossman D, et al. No-Test Medication Abortion: A Sample Protocol for Increasing Access During a Pandemic and Beyond. Contraception. 2020 Apr; epub ahead of print.

Raymond EG, Tan YL, Comendant R, et al. Simplified medical abortion screening: a demonstration project. Contraception. 2018 Apr;97(4):292-296.

Raymond EG, Weaver MA, Louie KS, et al. Effects of DMPA Injection Timing on Medical Abortion Efficacy and Repeat Pregnancy: An RCT. Obstet Gynecol. 2016 Oct;128(4):739-45.

Raymond EG, Weaver MA, Tan YL, et al. Effect of Immediate Compared With Delayed Insertion of Etonogestrel Implants on Medical Abortion Efficacy and Repeat Pregnancy. Obstet Gynecol. 2016 Feb;127(2):306-12.

Raymond, E. Anger HA, Chong E, et al. “False positive” urine pregnancy test results after successful medication abortion. Contraception, 2021, 103(6), pp.400-403.

Reeves MF, Fox MC, Lohr PA, et al. Endometrial Thickness Following Medical Abortion Is not Predictive of Subsequent Surgical Intervention. Ultrasound Obstet Gynecol. 2009;34(1):104-9.

Reeves MF, Kudva A, Creinin MD. Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. Contraception. 2008 Oct;78(4):332-5.

Reeves MF, Monmaney JA, Creinin MD. Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. Contraception. 2016 Feb;93(2):119-25.

Sääv I, et al. Early versus delayed insertion of intrauterine contraception after medical abortion – a randomized controlled trial. PLoS One. 2012;7(11):e48948.

Sanhueza Smith P, Peña M, Dzuba IG, et al. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. Reprod Health Matters. 2015 Feb;22(44 Suppl 1):75-82.

Schaff EA, Eisinger SH, Stadalius LS, et al. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.  Contraception 1999 Jan;59(1):1-6.

Schaff EA, Fielding SL, Westhoff C. Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 2002 Oct;66(4):247-250.

Schaff EA, Fielding SL, Westhoff C, Ellertson C, Eisinger SH, Stadalius LS, Fuller L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMA. 2000 Oct 18;284(15):1948-53. Erratum in: JAMA 2000 Nov 22-29;284(20):2597.

Schmidt-Hansen M, et al. Follow-up Strategies to Confirm the Success of Medical Abortion of Pregnancies Up to 10 Weeks’ Gestation: A systematic Review with Meta-Analysis. Am J Obstet Gynecol. 2019 Nov 9.

Schmidt-Hansen M, Lord J, Hasler E, Cameron S. Simultaneous compared to interval administration of mifepristone and misoprostol for medical abortion up to 10+0 weeks’ gestation: a systematic review with meta-analyses. BMJ Sex Reprod Health. 2020 Oct;46(4):270-278.

Schonberg D, Wang LF, Bennett AH, et al. The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: a systematic review. Contraception. 2014;90:480-7.

Seeber BE, Barnhart KT. Suspected ectopic pregnancy. Obstet Gynecol. 2006 Feb;107(2 Pt 1):399-413. Review. Erratum in: Obstet Gynecol. 2006 Apr;107(4):955.

Snyder H, et al. Managing pain for patients using Medication-Assisted Treatment for Opioid Use Disorder. National Abortion Federation (NAF), December 2018.

Sheldon WR, Durocher J, Dzuba IG, et al. Early Abortion with Buccal vs Sublingual Misoprostol Alone: a Multicenter Randomized Trial. Contraception. 2019 May;99(5):272-277.

Society of Family Planning Clinical Guideline. Medical management of first-trimester abortion. Contraception 89(3) 2014, pp. 148–161.

Stillman M, Owolabi O, Fatusi AO, et al. Women’s self-reported experiences using misoprostol obtained from drug sellers: a prospective cohort study in Lagos State, Nigeria. BMJ Open. 2020;10:e034670.

Tang OS, Chan CC, Ng EH, et al. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod. 2003 Nov;18(11):2315-8.

Tang OS, et al. The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol Hum Reprod. 2002;17:99–102.

Upadhyay UD, Raymond EG, Koenig LR, Coplon L, Gold M, Kaneshiro B, Boraas CM, Winikoff B. Outcomes and Safety of History-Based Screening for Medication Abortion: A Retrospective Multicenter Cohort Study. JAMA Intern Med. 2022 May 1;182(5):482-491.

Von Hertzen H, Huong NTM, Piaggio G,et al. Misoprostol dose and route after mifepristone for early medication abortion: a randomized controlled noninferiority trial. BJOG. 2010 Aug; 117:1186-1196.

Winikoff B, Dzuba IG, Chong E, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol. 2012 Nov;120(5):1070-6.

World Health Organization. Abortion Care Guideline. Geneva, 2022.


TEACH Abortion Training Curriculum Copyright © 2022 by UCSF Bixby Center for Global Reproductive Health. All Rights Reserved.